Synovus Financial Corp bought a new position in Bioverativ Inc (NASDAQ:BIVV) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 27,336 shares of the biotechnology company’s stock, valued at approximately $1,556,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Advisors Asset Management Inc. acquired a new stake in Bioverativ in the 3rd quarter valued at approximately $137,000. TCI Wealth Advisors Inc. acquired a new position in shares of Bioverativ in the third quarter worth $186,000. Canada Pension Plan Investment Board acquired a new position in shares of Bioverativ in the third quarter worth $194,000. ACG Wealth acquired a new position in shares of Bioverativ in the third quarter worth $205,000. Finally, Pinnacle Associates Ltd. acquired a new position in shares of Bioverativ during the third quarter worth $217,000. 96.03% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bioverativ Inc (NASDAQ BIVV) opened at $53.21 on Friday. Bioverativ Inc has a 1 year low of $40.00 and a 1 year high of $64.41.
A number of equities analysts recently commented on the stock. Piper Jaffray Companies reiterated an “overweight” rating and set a $71.00 target price on shares of Bioverativ in a research note on Monday, October 23rd. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $69.00 price target for the company in a research report on Thursday, October 19th. Morgan Stanley reissued an “underweight” rating and issued a $47.00 price target (up from $45.00) on shares of Bioverativ in a research report on Friday, October 6th. Royal Bank of Canada initiated coverage on shares of Bioverativ in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price target for the company. Finally, Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $60.93.
TRADEMARK VIOLATION NOTICE: “27,336 Shares in Bioverativ Inc (NASDAQ:BIVV) Purchased by Synovus Financial Corp” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://weekherald.com/2017/12/16/synovus-financial-corp-acquires-new-holdings-in-bioverativ-inc-bivv.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.